ArticleMedicine international
Premature immunosenescence in AYA gastrointestinal cancer: The metabolic-inflammatory-hormonal axis as an integrative framework: A systematic review.
Article in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global rise in gastrointestinal (GI) cancer among adolescents and young adults (AYAs; aged 15-39) represents a striking departure from traditional age-dependent epidemiology. In the present systematic review, it is proposed that premature immunosenescence may be a contributing driver of this trend and introduces the metabolic-inflammatory-hormonal axis as a working framework to explore these observations. Findings from PubMed/MEDLINE (1990-2024) were synthesized, focusing on high-impact studies and systematic reviews from the last 5 years, using keywords related to young-onset GI cancer, immunosenescence and metabolic inflammation. A PRISMA screening process was employed, with defined inclusion/exclusion criteria. The present systematic review identified several interconnected mechanisms that may drive premature immune aging in AYAs: i) T-cell exhaustion and thymic involution; ii) chronic inflammation fueled by the senescence-associated secretory phenotype and tumor-derived vesicles; and iii) metabolic perturbations, such as cholesterol buildup and lactate-mediated immunosuppression. Collectively, these changes may create an immunosuppressive microenvironment enriched with regulatory T cells, myeloid-derived suppressor cells and M2 macrophages. The metabolic-inflammatory-hormonal (M-I-H) axis integrates these pathways, potentially driving immune dysfunction independent of chronological age. The present systematic review emphasizes that this framework remains largely hypothetical, with numerous proposed associations awaiting direct experimental validation in AYA populations. Biomarkers including polymerase ε/polymerase δ1 mutations, microsatellite instabilityhigh/deficient mismatch repair-status, tumor mutational burden, circulating tumor DNA, and immune gene signatures may help guide precision therapy, although their specific relationship to premature immunosenescence requires further investigation. It was proposed in the present systematic review that targeting this axis, through metabolic modulation, anti-inflammatory strategies, hormonal interventions, or microbiota engineering, holds promise for treating AYA GI cancer. Ultimately, validating plasma biomarkers for early detection and assessing these combinatorial approaches in prospective trials will be critical to addressing this growing clinical challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.